Genmab’s Jan van de Winkel talks to Sukaina Virji about the excitement surrounding its multiple myeloma drug Darzalex (daratumumab), the potential of multiple sclerosis candidate ofatumumab, and how he’ll always be a scientist at heart.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Vyepti revenues rise by nearly 70% in the first quarter.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
